公开(公告)号：US20240065732A1

公开(公告)日：2024-02-29

申请号：US18498885

申请日：2023-10-31

申请人： Materna Medical, Inc.

发明人： Mark JURAVIC ,  Michael STEWART

IPC分类号： A61B17/42 ,  A61B1/303 ,  A61B1/31 ,  A61B5/00 ,  A61B5/22 ,  A61B17/02 ,  A61B17/34 ,  A61B90/00 ,  A61M29/02

CPC分类号： A61B17/42 ,  A61B1/303 ,  A61B1/31 ,  A61B5/22 ,  A61B5/227 ,  A61B5/4343 ,  A61B5/435 ,  A61B5/4836 ,  A61B17/0206 ,  A61B17/3423 ,  A61B90/03 ,  A61B90/06 ,  A61M29/02 ,  A61B2017/00119 ,  A61B17/02 ,  A61B17/3439

摘要： A vaginal dilation device is provided that may include any of a number of features. One feature of the vaginal dilation device is that it is configured to dilate vaginal tissue during labor to prevent tissue damage. Another feature of the vaginal dilation device is that it can be manually controlled to dilate vaginal tissue, or can be automatically controlled to dilate vaginal tissue. In some embodiments, the vaginal dilation device is configured to measure a force applied by the device to tissue. In other embodiments, the vaginal dilation device is configured to apply a constant force to tissue. In other embodiments, the vaginal dilation device is configured to expand at a constant rate. Methods associated with use of the vaginal dilation device are also provided.

公开(公告)号：US11835611B2

公开(公告)日：2023-12-05

申请号：US16603205

申请日：2018-04-06

申请人： The United States of America, as represented by the Secretary, Department of Health and Human Services

发明人： Peter J. Basser ,  Alexandru V. Avram

IPC分类号： G01V3/00 ,  G01R33/563 ,  A61B5/00 ,  A61B5/055 ,  G01R33/385 ,  G01R33/56 ,  G01R33/565 ,  A61B5/20

CPC分类号： G01R33/56341 ,  A61B5/004 ,  A61B5/0042 ,  A61B5/0044 ,  A61B5/055 ,  G01R33/385 ,  G01R33/5608 ,  G01R33/56509 ,  A61B5/20 ,  A61B5/4029 ,  A61B5/416 ,  A61B5/4244 ,  A61B5/4255 ,  A61B5/4343 ,  A61B5/4381 ,  A61B5/4519

摘要： Isotropic generalized diffusion tensor imaging methods and apparatus are configured to obtain signal attenuations using selected sets of applied magnetic field gradient directions whose averages produce mean apparent diffusion constants (mADCs) over a wide range of b-values, associated with higher order diffusion tensors (HOT). These sets are selected based on analytical descriptions of isotropic HOTs and the associated averaged signal attenuations are combined to produce mADCs, or probability density functions of intravoxel mADC distributions. Estimates of biologically-specific rotation-invariant parameters for quantifying tissue water mobilities or other tissue characteristics can be obtained such as Traces of HOTs associated with diffusion and mean t-kurtosis.

公开(公告)号：US20230143619A1

公开(公告)日：2023-05-11

申请号：US17300735

申请日：2021-11-08

申请人： Francis Jancik

发明人： Francis Jancik

IPC分类号： A61B5/00 ,  A61B5/01 ,  G01J5/00

CPC分类号： A61B5/4343 ,  A61B5/01 ,  A61B5/4375 ,  A61B5/743 ,  G01J5/0025

摘要： A method of increasing the probability that a woman and/or a father will conceive either INFERTILITY or MISCARRIAGE before or after conception, comprising the steps of determining an infrared body temperature of the mother, determining an infrared body temperature of the father, categorizing the determined infrared body temperatures of the mother and the father as either “very extremely low” (Infertility) or “very extremely high” (Miscarriage) according to a predetermined categorization criteria, and correlating the stress level of the mother and the father according to a correlation where in the case of very extremely low temperature for either or both the mother and the father, the probability of INFERTILITY, according to a predetermined categorization criteria, and correlating the stress level of the mother and the father according to a correlation where in the case of very extremely high temperature for either or both the mother and the father, the probability of MISCARRIAGE. The information derived is applied by using sex probabilities according to the criteria where procuring conception of the “stillborn child” (Miscarriage) or “not exited” (Infertility) without alteration of the infrared body temperature of the mother and father if the indicated probability of not conceiving a child, or procuring conception of stillborn baby after alerting the infrared body temperatures of mother and/or father to increase the indicated probability of not conceiving an alive child of either of

公开(公告)号：US10010703B2

公开(公告)日：2018-07-03

申请号：US15822625

申请日：2017-11-27

申请人： POP TEST ABUSE DETERRENT TECHNOLOGY LLC

发明人： Randice Lisa Altschul ,  Neil David Theise ,  Razvan Andrei Ene ,  Myron Rapkin ,  Rebecca O'Brien

IPC分类号： A61M31/00 ,  G06F19/00 ,  A61K45/06 ,  A61K31/58 ,  A61B5/00

CPC分类号： A61M31/002 ,  A61B5/002 ,  A61B5/0022 ,  A61B5/01 ,  A61B5/14539 ,  A61B5/14542 ,  A61B5/14546 ,  A61B5/4343 ,  A61B5/4839 ,  A61B5/4845 ,  A61B2560/0214 ,  A61K9/0053 ,  A61K9/0097 ,  A61K31/58 ,  A61K45/06 ,  A61M5/14 ,  A61M2205/33 ,  A61M2205/3303 ,  A61M2205/3306 ,  A61M2205/3523 ,  A61M2205/3553 ,  A61M2205/3569 ,  A61M2205/50 ,  A61M2205/52 ,  A61M2205/8206 ,  A61M2205/8268 ,  A61M2230/005 ,  A61M2230/20 ,  A61M2230/201 ,  A61M2230/208 ,  A61M2230/50 ,  A61M2250/00 ,  G06F19/00 ,  G06F19/3456 ,  G06F19/3462 ,  G16H20/10 ,  G16H20/13 ,  G16H40/63 ,  H05K999/99 ,  Y02A90/26 ,  A61K2300/00

摘要： This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.

公开(公告)号：US09918673B2

公开(公告)日：2018-03-20

申请号：US14663453

申请日：2015-03-20

申请人： Stephen Dugan

发明人： Stephen Dugan

IPC分类号： A61B5/00 ,  A61B5/11 ,  A61B5/021 ,  A61B5/08 ,  A61B5/107 ,  A61B5/145 ,  A61B5/1455

CPC分类号： A61B5/4343 ,  A61B5/0077 ,  A61B5/021 ,  A61B5/065 ,  A61B5/067 ,  A61B5/08 ,  A61B5/1072 ,  A61B5/1073 ,  A61B5/1075 ,  A61B5/1107 ,  A61B5/1114 ,  A61B5/1116 ,  A61B5/1117 ,  A61B5/1118 ,  A61B5/1121 ,  A61B5/14542 ,  A61B5/14552 ,  A61B5/4356 ,  A61B5/4362 ,  A61B5/6823 ,  A61B5/6831 ,  A61B5/6832 ,  A61B5/7275 ,  A61B5/746 ,  A61B2503/02 ,  A61B2562/0219 ,  G06F19/00

摘要： The various embodiments herein relate to systems, devices, and methods for tracking abdominal orientation and activity for purposes of preventing or treating conditions of pregnancy or other types of medical conditions. In certain specific embodiments, the system, device, or method relates to identifying abdominal orientation risk values, calculating and updating a cumulative risk value, comparing the cumulative risk value to a threshold, and outputting a warning when the cumulative risk value crosses the threshold.

公开(公告)号：US09878139B2

公开(公告)日：2018-01-30

申请号：US15494077

申请日：2017-04-21

申请人： Pop Test Abuse Deterrent Technology LLC

发明人： Randice Lisa Altschul ,  Neil David Theise ,  Razvan Andrei Ene ,  Myron Rapkin ,  Rebecca O'Brien

IPC分类号： A61M31/00 ,  A61K9/00 ,  A61K31/58 ,  A61B5/00 ,  A61B5/145 ,  A61B5/01

CPC分类号： A61M31/002 ,  A61B5/002 ,  A61B5/0022 ,  A61B5/01 ,  A61B5/14539 ,  A61B5/14542 ,  A61B5/14546 ,  A61B5/4343 ,  A61B5/4839 ,  A61B5/4845 ,  A61B2560/0214 ,  A61K9/0053 ,  A61K9/0097 ,  A61K31/58 ,  A61K45/06 ,  A61M5/14 ,  A61M2205/33 ,  A61M2205/3303 ,  A61M2205/3306 ,  A61M2205/3523 ,  A61M2205/3553 ,  A61M2205/3569 ,  A61M2205/50 ,  A61M2205/52 ,  A61M2205/8206 ,  A61M2205/8268 ,  A61M2230/005 ,  A61M2230/20 ,  A61M2230/201 ,  A61M2230/208 ,  A61M2230/50 ,  A61M2250/00 ,  G06F19/00 ,  G06F19/3456 ,  G06F19/3462 ,  G16H20/13 ,  G16H40/63 ,  Y02A90/26 ,  A61K2300/00

摘要： This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.

公开(公告)号：US20180014816A1

公开(公告)日：2018-01-18

申请号：US15209221

申请日：2016-07-13

申请人： WITHINGS

发明人： Nadine Buard ,  Ruiyi Yang ,  Marc Besnard ,  Cédric Hutchings

IPC分类号： A61B10/00 ,  A61B5/11 ,  A61B5/024 ,  A61B5/00 ,  A61B5/0205

CPC分类号： A61B10/0012 ,  A61B5/0002 ,  A61B5/01 ,  A61B5/0205 ,  A61B5/024 ,  A61B5/02416 ,  A61B5/02438 ,  A61B5/1118 ,  A61B5/1123 ,  A61B5/4325 ,  A61B5/4343 ,  A61B5/4809 ,  A61B5/681 ,  A61B5/6892 ,  A61B5/743 ,  A61B2010/0019 ,  A61B2010/0029 ,  A61B2562/0219 ,  A61B2562/0271

摘要： A method for determining a fertility period for a female human individual (FU), carried out in a device comprising a controller, a non-invasive heart sensor placed in contact or opposite to a portion of the skin of the individual, during the sleep of the individual, the heart sensor being configured to sense heart pulses of the individual and the controller being configured to determine the heart rate, the method comprising the following steps: /a/ collecting, at the sensor, heart pulses signals of the individual; /b/ extracting therefrom, at the controller, current heart rate during a night; /c/ calculating a minimal sleep heart rate denoted MSHR(i), over the night; /d/ comparing MSHR(i) with values of MSHR(k) recorded previously, and/or comparing MSHR(i) with a long term average of the minimal sleep heart rate values denoted LTHR; /e/ deducing therefrom a current ovulation probability index, according to a predefined criteria; /f/ if the ovulation probability index is higher than a predefined threshold denoted PTH, notify the individual with a fertility time window.

公开(公告)号：US20170259050A1

公开(公告)日：2017-09-14

申请号：US15494077

申请日：2017-04-21

申请人： Pop Test LLC

发明人： Randice Lisa ALTSCHUL ,  Neil David Theise ,  Razvan Andrei Ene ,  Myron Rapkin ,  Rebecca O'Brien

IPC分类号： A61M31/00 ,  A61B5/01 ,  A61B5/00 ,  A61B5/145 ,  A61K9/00 ,  A61K31/58

CPC分类号： A61M31/002 ,  A61B5/002 ,  A61B5/0022 ,  A61B5/01 ,  A61B5/14539 ,  A61B5/14542 ,  A61B5/14546 ,  A61B5/4343 ,  A61B5/4839 ,  A61B5/4845 ,  A61B2560/0214 ,  A61K9/0053 ,  A61K9/0097 ,  A61K31/58 ,  A61K45/06 ,  A61M5/14 ,  A61M2205/33 ,  A61M2205/3303 ,  A61M2205/3306 ,  A61M2205/3523 ,  A61M2205/3553 ,  A61M2205/3569 ,  A61M2205/50 ,  A61M2205/52 ,  A61M2205/8206 ,  A61M2205/8268 ,  A61M2230/005 ,  A61M2230/20 ,  A61M2230/201 ,  A61M2230/208 ,  A61M2230/50 ,  A61M2250/00 ,  G06F19/00 ,  G06F19/3456 ,  G06F19/3462 ,  G16H20/13 ,  G16H40/63 ,  Y02A90/26 ,  A61K2300/00

摘要： This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.

公开(公告)号：US20170185739A1

公开(公告)日：2017-06-29

申请号：US14980799

申请日：2015-12-28

申请人： CERNER INNOVATION, INC.

发明人： Patrizia Smouse Gomez ,  Jessica Alford ,  Krystal Cunningham ,  Ginger Querner ,  Justin Peterson ,  Yash Goyal ,  Hemin Merchant ,  Peng Li ,  Amy Stafford

IPC分类号： G06F19/00 ,  A61B5/02

CPC分类号： A61B5/02042 ,  A61B5/01 ,  A61B5/021 ,  A61B5/024 ,  A61B5/0816 ,  A61B5/4343 ,  G01G19/00 ,  G01G19/44 ,  G16H10/60 ,  G16H50/30

摘要： Methods and a system are provided for assessing postpartum hemorrhage risk and postpartum hemorrhage stages in a clinical setting. Generally, a clinician may indicate that the mass of several bloody items, indicated in type and quantity, is to be measured using a scale. The mass of bloody items is compared to the known unused dry mass of such items in order to accurately determine the quantitative blood loss (QBL) of a patient at the bedside. The cumulative QBL can be updated by weighing additional items. Based on the cumulative QBL, the patient's vital signs, and other factors, a corresponding hemorrhage stage is identified and communicated to the clinician. Recommendations specific to the hemorrhage stage are provided to a clinician. Some recommendations are selectable actions that trigger automatic placement of medical orders and notifications to relevant medical services, such as a blood bank or anesthesia.

公开(公告)号：US20170172498A1

公开(公告)日：2017-06-22

申请号：US15117736

申请日：2015-02-13

申请人： NIR Technologies Inc.

发明人： Hormoz Azizian

IPC分类号： A61B5/00 ,  G06F19/00

CPC分类号： A61B5/4872 ,  A61B5/0075 ,  A61B5/4343 ,  A61B5/486 ,  A61B5/7225 ,  A61B5/7257 ,  A61B2503/02 ,  A61B2576/00 ,  G06F19/00 ,  G06F19/3475

摘要： The present invention provides a method for measuring the body fat percent and fat accretion during pregnancy, which preferably utilizes a Fourier transform near infrared spectroscopy (FT-NIR) fat determination method. The FT-NIR results can be used to measure and monitor body fat percent, and used to measure the mother's fat accretion rate. A method to monitor weight gain in a pregnant subject is provided wherein the body fat percentage of the subject is maintained at a constant level during gestation, and the subject's fat accretion rate is monitored so as to follow the fat accretion rate provided by using pre-defined fat accretion determination formulae. By measurement of the body fat percent and fat accretion rates, the weight gain of a subject can be monitored and/or controlled during pregnancy.